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Ubiquitin–proteasome degradationTight control between activation and attenuation of granulocyte colony stimulating factor receptor (G-CSFR)
signaling is essential to regulate survival, proliferation and differentiation of myeloid progenitor cells.
Previous studies demonstrated negative regulation of G-CSFR through endosomal–lysosomal routing and
ubiquitin–proteasome mediated degradation. However, very few E3 ubiquitin ligases are known to target
G-CSFR for ubiquitin–proteasome pathway. Here we identiﬁed F-box and WD repeat domain-containing 7
(Fbw7), a substrate recognizing component of Skp–Cullin–F box (SCF) E3 ubiquitin Ligase physically associ-
ates with G-CSFR and promotes its ubiquitin-mediated proteasomal degradation. Our data shows that
Fbw7 also interacts with and degrades G-CSFR-T718 (a truncated mutant of G-CSFR found in severe congen-
ital neutropenia/acute myeloid leukemia (SCN/AML patients)) though at a quite slower rate compared to
G-CSFR. We further show that glycogen synthase kinase 3 beta (GSK3β), like Fbw7 also targets G-CSFR
and G-CSFR-T718 for degradation; however, Fbw7 and GSK3β are interdependent in targeting G-CSFR/
G-CSFR-T718 for degradation because they are unable to degrade G-CSFR individually when either of them
is knocked down. We further show that Fbw7 mediated downregulation of G-CSFR inhibits signal transducer
and activator of transcription 3 (STAT3) phosphorylation which is required for G-CSF dependent granulocytic
differentiation. In addition, our data also shows that inhibition of Fbw7 restores G-CSFR signaling leading
to enhanced STAT3 activity resulting in massive granulocytic differentiation. These data indicate that Fbw7
together with GSK3β negatively regulates G-CSFR expression and its downstream signaling.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Granulocyte colony stimulating factor receptor (G-CSFR) mediat-
ed signaling critically regulates survival, proliferation and differentia-
tion of myeloid progenitor cells. It is crucial for the hematopoietic
development because G-CSF or G-CSFR deﬁcient mice acquire severe
congenital neutropenia (SCN) with impaired granulopoietic re-
sponses to infection [1]. G-CSF binding to G-CSFR elicits the down-
stream signaling by activating Janus tyrosine kinase (JAK)/signal
transducer and activator of transcription (STAT), Ras/Raf/MAP kinase
and PKB/AKT pathways. This initiates proliferation and survival of
myeloid progenitors, subsequent cell cycle arrest and ultimately
advances to differentiation resulting in neutrophil formation [2]. How-
ever, a balance between activation and attenuation of G-CSFR signaling
is essential for maintaining homeostatic levels of neutrophils in bloodery and Development Division,
tor-10, Jankipuram Extension,
790765; fax: +91 5222771941.
).
rights reserved.circulation. Mutations resulting in carboxy-terminal truncation in
G-CSFR gene have been reported in patients with severe congenital
neutropenia (SCN) transformed to acute myeloid leukemia (AML).
The truncated mutants of G-CSFR are constitutively active and trans-
duce hyper proliferative responses upon G-CSF stimulation without
neutrophil differentiation [3]. Therefore, downregulation of “activated
G-CSFR” is important to keep a check on G-CSFR mediated signaling in
order to protect cells from over-stimulation.
Attenuation of G-CSF signaling is controlled throughmultiplemech-
anisms such as dephosphorylation of G-CSFR through tyrosine phos-
phatases (SHP-1 and SHP-2) and inositol phosphatases (SHIP1) [4–6];
G-CSFR protein-destabilization either by proteolytic cleavage through
neutrophil elastase or ubiquitination dependent degradation [7].Major-
ity of the mechanisms explain the termination of G-CSFR signaling
through SOCS proteins by inhibition of JAK kinase activity or by recruit-
ment of elongins B and C to SOCS box to form an E3 ubiquitin ligase
complex that directs G-CSFR to the endosomal–lysosomal degradation
route [8,9]. Moreover, recent studies have also shown ubiquitinmediat-
ed proteasome-dependent degradation of G-CSFR [10]. However, the
E3 ubiquitin ligases, regulating the rate-limiting step in ubiquitin–
proteasome degradation of G-CSFR have largely remained unexplored.
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the constitutive distribution of G-CSFR.
F box protein Fbw7 (also known in cdc4) is a component of the
SCF (Skp–Cullin–F box) ubiquitin ligase that recognizes and binds to
its substrates through a consensus phospho-binding motif (T/S-P-X-
X-S/T/D/E) known as Cdc4-Phospho Degron (CPD). The recognition
of CPDs by SCFFbw7 is regulated by phosphorylation of the substrate
at threonine/serine residue within CPD motif. This phosphorylated
CPD binds with three conserved arginine residues within WD40 re-
peats in the C-terminus of Fbw7 [11]. Majority of the known Fbw7
substrates are phosphorylated by GSK3β such as c-myc [12,13],
c-jun [14], MCL-1 [15], C/EBPα [16,17], KLF5 [18,19], SREBP1 [20], cy-
clin E [21] and PGC-1 [22] (Table 1).
In this study for theﬁrst timewe show that Fbw7negatively regulates
G-CSFR by targeting it to degradation through the ubiquitin–proteasome
pathway. Our data shows that Fbw7 facilitates ubiquitination and degra-
dation of G-CSFR through multiple potential phosphodegrons present in
G-CSFR (Table 1). This process is promoted by GSK3βwhich presumably
phosphorylates G-CSFR in its potential CPDs and thus facilitates its recog-
nition by Fbw7 for subsequent ubiquitin–proteasome degradation. We
show that Fbw7 also targets mutant G-CSFR-T718 for degradation,
though at a relatively slower rate than the wild type G-CSFR. We further
show that Fbw7 mediated downregulation of G-CSFR inhibits down-
stream signaling and subsequent biological consequences. On the con-
trary, inhibition of Fbw7 restores G-CSFR signaling leading to enhanced
STAT3 activity and granulocytic differentiation.
2. Materials and methods
2.1. Cell culture, transfection and siRNA introduction
Human embryonic kidney cell line HEK293T (293T) and IL-3 de-
pendent murine myeloid 32Dcl3 cells were obtained from ATCC.
293T cells were cultured as previously described [23]. 32Dcl3 cells
were maintained in RPMI-1640 medium supplemented with 10%Table 1
Putative CPD sequences in G-CSFr compared with CPD sequences in known substrates
of FBW7. Few sequences do not exactly match with CPD consensus sequences however
like in mTOR they may also be targeted by Fbw7.
Consensus CPD sequence: (S/T)P-X-X-(S/T/D/E)
Potential
phosphorylation
site
Putative CPD
sequence in
G-CSFr
Other substrates
containing similar
CPD sequences
Kinase Ref,
S322 S P S L E Cyclin E: pT P D K E
KLF5: pT P D L D
not known
GSK3β (pT)
[21]
[18,19]
T620 T P E G S Cyclin E pT P P Q pS GSK3β(pT) [21]
T802a T P A P S c-myc pT P P L S cdk2 (pS) [12,13]
c-jun pT P P L S GSK3β (pT) [14]
SREBP 1: pT P P P pS GSK3β (pT) [20]
KLF5: pS P P S S
pT P P P S
GSK3β (pT,pS)
GSK3β (pS)
[18,19]
PGC1: pT P E pS P GSK3β (pT)
p38 MAPK (pT,pS)
[22]
T690 T P P I T C/EBPα: pT P P P pT GSK3β (pT, pT) [16,17]
PGC1: pT P P T pT GSK3β (pT)
p38 MAPK (pT)
[22]
S795a S P L G T MCL-1: pS L P S pT GSK3β (pS, pT) [15]
S214 SPQLCb mTOR: T P S I H Not known [30]
S238 SPEAAb
T420 TPVVFb
T505 TPLYQb
S557 SPLTHb
S651 SPNRKb
S758 SPTSPb
S761 SPGPGb
T781 TPSPKb
S783 SPKSYb
a CPD motifs absent in truncated mutant G-CSFr-T718.
b These motifs could also act as CPD.fetal bovine serum (FBS), 1% PenStrep (Gibco) and 10 ng/mL murine
IL-3 (Prospec) at 37 °C and 5% CO2. Expression plasmids were
transfected using LTX (Invitrogen) while siRNAs were transfected
with DhermaFECT (Dhermacon) as per manufacturer's protocol. ON
TARGETplus SMARTpool siRNAs (Dhermacon) for hFbw7, mFbw7
and hGSK3β were used, sicontrol non-targeting siRNA#1 was used
as control. Expression plasmids for pMX-IRES-GFP-HA-G-CSFR and
pMX-IRES-GFP-HA-G-CSFR-T718 were kind gifts from Dr. Stefan N.
Constantinescu [24]; pFLAG-Fbw7α, pFLAG-Fbw7β, pFLAG-Fbw7γ,
pFLAG-Fbw7αΔF and pFLAG-dnFbw7αWD were kind gifts from
Dr. E. Clurman [25]. V5-GSK3β and HA-GSK3βS9A were kind gifts
from D. Helen Piwnica-Worms and Dr. William G. Kaelin respectively
[14,26].
2.2. Cycloheximide half-life experiments
293T cells were transiently transfected with 0.5 μg HA-G-CSFR/
G-CSFR-T718 alone or with 1 μg Flag-Fbw7α or Fbw7αΔF or
dnFbw7αWD. 48 h post transfection, cycloheximide (CHX) (Enzo Life
Sciences) was added to a ﬁnal concentration of 80 μg/mL to inhibit
new protein synthesis for indicated time points followed by whole
cell extracts (WCEs) preparation in RIPA buffer and immunoblotted
with anti-HA.
2.3. Peripheral blood mononuclear cells (PBMCs) isolation
PBMCs were isolated from healthy volunteer blood samples using
histopaque-1077 (Sigma). Isolated PBMCs were grown in RPMI-1640
supplemented with 10% FBS. PBMCs were transiently transfected
with Fbw7α using Lipfectamine LTX (Invitrogen) according to the
manufacturer's protocol. 48 h post transfection, WCEs were prepared
and subjected to immunoblot against anti-G-CSFR antibody to assess
endogenous levels of G-CSFR.
2.4. Morphology study
32Dcl3 cells were transfected with dnFbw7WD or siFbw7 in dupli-
cates. 48 h post transfection one set was stimulated with 100 ng/mL
G-CSF (Millipore) and the other was left untreated. Transfected
32Dcl3 cells were then maintained in IL-3 deprived complete
RPMI-1640 to assess the morphology. Cells after 3, 9 and 12 days
were cytospun, air dried and stained with May-Grunwald and Giemsa
(Sigma) and subsequently analyzed under microscope.
2.5. Co-immunoprecipitation and in vivo ubiquitination assay
Co-immunoprecipitation was performed as previously described
[27–29]. Brieﬂy, 293T cells were transfectedwith the indicated plasmids,
namely G-CSFR/G-CSFR-T718 and Fbw7α, Fbw7β or Fbw7γ. 48 h post
transfection 10 μM MG132 or 10 μM Lactacystin (Sigma) was added to
the cells for 6 h, wherever used. Whole cell extracts (WCEs) were pre-
pared using RIPA lysis buffer. Equal amounts of pre-cleared WCEs were
incubated at 4 °C for 4 h with pre-equilibrated Protein A/G agarose
beads (Millipore) and either anti-G-CSFR or anti-GFP antibody was
used to immunoprecipitate G-CSFR/G-CSFR-T718 or anti-cdc4 and anti-
GSK3β antibody to immunoprecipitate endogenous Fbw7 andGSK3β re-
spectively from 293T cells. Co-precipitates were further immunoblotted
with the indicated antibodies. PBMCs isolated from healthy volunteer
bloodwere treatedwith orwithout 10 μMMG132.WCEswere prepared
using RIPA lysis buffer and endogenousG-CSFRwas immunoprecipitated
as described above.
In vivo ubiquitination was performed as described previously [30].
Brieﬂy, 293T cells were transfected with the indicated plasmids; 48 h
post transfection, 10 μMMG132 was added to the cells for 6 h. WCEs
were subjected to co-immunoprecipitation with anti-GFP antibody to
pull out G-CSFR. Co-precipitates were then immunoblotted with
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are provided in the Appendix A.
2.6. Immunoﬂuorescence
HEK293T (293T) cells grown on a coverslip in six well ﬂasks were
transfected with HA-G-CSFR together with Fbw7α. 24 h post trans-
fection, cells were ﬁxed with 4% paraformaldehyde, permebealized
with 0.5% Triton X-100 in 1× PBS and further blocked with 1% BSA.
Cells were immunostained with rabbit G-CSFR (1:250) and mouse
Flag M2 (1:250) antibody overnight at 4 °C. The next day, cells
were washed with 1× PBS and further incubated with anti-rabbit
(alexaﬂuor 488) and anti-mouse (alexaﬂuor 594) secondary antibod-
ies (1:500) respectively. Coverslips were washed, dried and mounted
with vectashield (vector, H-1000). Images were captured using Leica
DMI6000B microscope. PBMCs from the healthy volunteer's blood
were isolated and cytospun on slides. Cells were subjected to similar
protocol described above and subsequently immunostained with
anti-rabbit G-CSFR (1:250) and anti-mouse Fbw7 (1:250) antibody
overnight at 4 °C. The next day, cells were washed with 1× PBS and
further incubated with anti-rabbit alexaﬂuor 488 and anti-mouse
alexaﬂuor 594 secondary antibodies (1:500) respectively. Images
were captured using Leica DMI6000B microscope.
3. Results
3.1. Fbw7 negatively regulates steady state levels of G-CSFR
The apparent role of ubiquitin–proteasome pathway in negative
regulation of G-CSFR signaling prompted us to search for E3 ubiquitin
ligases that may target G-CSFR for degradation via the ubiquitin–
proteasome pathway [10]. Thorough analysis of G-CSFR protein se-
quence revealed the presence of several potential Cdc4-Phospho
Degron (CPD) motifs that may be recognized by Fbw7, a substrate
recognizing component of SCF E3 ubiquitin ligase complex (SCFFbw7)
for targeting them to ubiquitin–proteasome degradation [31]. Five
such potential CPDs starting at amino acid positions S322, T620,
T690, S795 and T802 matching to the CPDs in other known substrates
of Fbw7 are present in G-CSFR (Table 1). In addition few other motifs
showing modest homology to CPD consensus sequences are also
present in G-CSFR [32]. The presence of these scattered CPDs in
G-CSFR prompted us to investigate whether G-CSFR is also a substrate
for Fbw7. To address this, WCEs of HEK293T cells (here onwards
293T) transfected with HA-G-CSFR and indicated amounts of Fbw7
isoforms were immunoblotted with anti-HA antibody which showed
that all the three isoforms downregulated G-CSFR protein expression
(Fig. 1A). Further, since Fbw7α is the most highly expressed and stable
isoform of Fbw7 [33], we co-transfected HA-G-CSFR with increasing
amounts of Fbw7α (0.5, 1.0 and 2.0 μg) in 293T and immunoblotted
with G-CSFR which showed an inverse correlation between G-CSFR
and Fbw7α expression; persistent downregulation of G-CSFR protein
expressionwith increasing doses of Fbw7αwas seen (Fig. 1B). This sug-
gested that Fbw7might negatively regulate G-CSFR protein steady state
levels. To further verify that downregulation of G-CSFR is Fbw7α specif-
ic, we over expressed HA-G-CSFR with Fbw7α deletion mutants:
non-functional Fbw7αΔF (lacks the F box domain which binds directly
to the SKP1 component of SCF ubiquitin ligase) and dnFbw7αWD (con-
tains only a stretch ofWD40 repeats, the protein interaction domains in
Fbw7 which bind to the substrate) in 293T cells. Contrary to the wild
type Fbw7α, G-CSFR expression was restored with Fbw7 mutants;
conﬁrming G-CSFR downregulation is Fbw7 speciﬁc (Fig. 1C). In fact,
unlike Fbw7α, increasing amounts of Fbw7αΔF and dnFbw7αWD rather
stabilized the G-CSFR expression (Appendix A, Fig. S1). In order to as-
certain these ﬁndings in a physiologically relevant model, we used
32Dcl3 cells, a murine myeloid cell line that is used as a model to
study G-CSFR signaling [34]. We co-transfected G-CSFR with differentisoforms of Fbw7 (Fbw7α, Fbw7β and Fbw7γ) in 32Dcl3, 24 h post
transfection, cells were lysed, resolved on 8% SDS-PAGE and
immunoblotted with HA antibody which afﬁrmed that Fbw7 indeed
downregulates G-CSFR expression (Fig. 1D). Since G-CSFR generates
unique signals for the production of peripheral blood mononuclear
cells (PBMCs), we assessed endogenous G-CSFR expression by tran-
siently transfecting Fbw7α in PBMCs isolated from healthy volunteers.
48 h post transfection, cells were harvested, resolved on 8% SDS-PAGE
and immunoblottedwith anti-G-CSFR antibodywhich yielded three en-
dogenous bands in the 80–130 kDa range, possibly representing differ-
ent glycosylated states of G-CSFR [35]; as expected, the expression of all
the three bands are reduced in Fbw7α transfected PBMCs (Fig. 1E)
which further strengthens our ﬁnding that Fbw7 negatively regulates
steady state levels of G-CSFR. We next asked if Fbw7 negatively regu-
lates G-CSFR expression, should the knockdown of Fbw7 by siFbw7 re-
store endogenous G-CSFR expression? To address this, we knocked
down endogenous Fbw7 by siFbw7 in a physiologically relevant cell
system, 32Dcl3. We observed that siFbw7 mediated knockdown of
Fbw7 led to increase in endogenous G-CSFR expression. Further, as
expected, IL3 replacement with G-CSF stimulated endogenous G-CSFR
expression in these cells and when Fbw7 was knocked down with
siFbw7, endogenous G-CSFR expression alleviated even in the absence
of G-CSF stimulation conﬁrming an inverse relationship between
G-CSFR and Fbw7 (Fig. 1F).3.2. Fbw7 promotes G-CSFR degradation primarily through
ubiquitin–proteasome pathway
Because Fbw7 is an E3 ubiquitin ligase, we sought to assess if
downregulation of G-CSFR expression by Fbw7 is mediated by its ligase
activity leading to ubiquitin–proteasome-dependent degradation. Sub-
stantial restoration of G-CSFR protein expression even in the presence
of Fbw7α by active proteasome inhibitor MG132 (Fig. 2A) endorsed
our assumption that Fbw7 (through its E3 ubiquitin ligase activity) ap-
parently targets G-CSFR for ubiquitin–proteasome mediated degrada-
tion [36]. Further, cells were also treated with lysosomal inhibitor
Baﬁlomycin A1 either alone or together with MG132 to test whether
degradation of ubiquitinated G-CSFR also occurs through lysosomal-
pathway in addition to ubiquitin–proteasome pathway [37]. Immuno-
blot of the lysates revealed that MG132 majorly restored the G-CSFR
protein level in 293T cells. Although Baﬁlomycin A1 also slightly miti-
gated Fbw7mediated G-CSFR downregulation,much enhanced restora-
tion of G-CSFR expression was observed with MG132, suggesting
G-CSFR downregulation through Fbw7 is primarily mediated through
ubiquitin–proteasome pathway (Fig. 2A). To further strengthen these
ﬁndings, we performed in vivo ubiquitination assay using WCEs from
293T cells co-transfected with plasmids expressing Fbw7α, G-CSFR
and His-Ubiquitin. G-CSFR was immunoprecipitated with anti-GFP
while the co-precipitates were immunoblotted with anti-His antibody
after resolving on 8% SDS-PAGE. Heavy G-CSFR ubiquitination as a lad-
der was observed in Fbw7α, G-CSFR and His-Ubiquitin co-transfected
cells while almost no ubiquitination was observed in cells co-
transfected with G-CSFR, His-Ubiquitin and either of the deletion mu-
tants of Fbw7 (Fbw7αΔF and dnFbw7αWD) suggesting Fbw7 indeed
promotes ubiquitination of G-CSFR. Interestingly, a rather more intense
ubiquitinated ladder pattern was observed in cells treated with MG132
which apparently stabilized the ubiquitinated G-CSFR by inhibiting
proteasome machinery (Fig. 2B). In order to further consolidate our
ﬁnding that Fbw7 is affecting steady state levels of G-CSFR protein, we
determined the half-life of G-CSFR after inhibiting new protein synthe-
sis by cycloheximide (CHX). Immunoblot as shown in Fig. 2Ci clearly
demonstrates that Fbw7α markedly reduces the half-life of G-CSFR,
while Fbw7 deletion mutants have no effect. The graphical analysis
(Fig. 2Cii) indicates that Fbw7α led to a signiﬁcant decrease in the
half-life of G-CSFR from 120 min to less than 60 min. Detailed analysis
BIB: HA
IB: Flag
IB: β-actin
Fbw7α (µg)               2               0.5     1       2 
0.5µg G-CSFR
42kDa
130kDa
100kDa
A
0.5  1.0  0.5  1.0  0.5  1.0    (µg)
G-CSFR (0.5µg)        +     +     +     +     +     +     +
Fbw7α Fbw7β Fbw7γ
IB: HA
IB: Flag
IB: β-actin
* α
β
γ
42kDa
48kDa
75kDa
100kDa
130kDa
G-CSFR            +       +      +      + 
IB: HA
IB: Flag
IB: β-actin
dnFbw7αWD
C
130kDa
100kDa
42kDa
D
E
Fbw7α - +     
PBMCs
IB
: G
-CSFR
IB: Flag
IB: β-actin
Endogenous  
G
-CSFR 85kDa
100kDa
130kDa
100kDa
42kDa
Fbw7 γ (1.0µg)        - - - - +
Fbw7β (1.0µg)        - - - +      -
Fbw7α (1.0µg)        - - +       - -
G-CSFR (0.5µg)     - +       +      +      + 
α
β
γ
IB: HA
IB: Flag
IB: β-actin 42kDa
48kDa
75kDa
100kDa
130kDa
+GCSF
D2     D3
siFBW7
- GCSF
D2     D3
siFBW7
+ GCSF
D2    D3
IB
: G
-CSFR
Endogenous  
G
-CSFR 
IB: FBW7
130kDa
100kDa
75kDa
100kDa
F
Fig. 1. Fbw7 negatively regulates steady state levels of G-CSFR. (A) 293T was transiently transfected with 0.5 μg HA tagged G-CSFR with indicated amount of Flag-Fbw7α,
Flag-Fbw7β and Flag-Fbw7γ. Post 48 h of transfection WCEs were prepared, resolved on 8% SDS-PAGE and immunoblotted with anti-HA and anti-Flag-M2 antibodies to detect
G-CSFR, Fbw7α, Fbw7β, and Fbw7γ expression respectively. β-actin was probed as loading control. (*indicates non speciﬁc band, possibly unstriped G-CSFR). (B) 0.5 μg of
G-CSFR co-transfected with increasing amounts of Flag-Fbw7α (0.5, 1.0 and 2.0 μg). 48 h post transfection, WCEs were prepared, resolved on SD-PAGE and immunoblotted
with anti-HA and anti-Flag-M2 antibodies respectively. β-actin was probed as loading control (C) 0.5 μg of G-CSFR was co-transfected with 1.0 μg of Flag-Fbw7α or Fbw7αΔF
or dnFbw7αWD in 293T cells. WCEs were prepared after 48 h of transfection, resolved on SDS-PAGE and immunoblotted with anti-HA and anti-Flag-M2 antibodies respectively
(D) 0.5 μg of G-CSFR was transfected with or without 1.0 μg of Flag-Fbw7α, Flag-Fbw7β or Flag-Fbw7γ in 32Dcl3 cells. 48 h post transfection, WCEs were prepared and
immunoblotted with anti-HA and anti-Flag-M2 antibodies to detect G-CSFR and Fbw7 respectively. β-actin was probed as loading control. (E) PBMCs isolated from healthy volun-
teers were transfected with 2.0 μg of Fbw7α. 48 h post transfection, WCEs were prepared, resolved on SDS-PAGE and immunoblotted with anti-G-CSFR antibody for endogenous
G-CSFR and anti-Flag-M2 antibody for Fbw7α. The arrows indicate the multiple bands of endogenous G-CSFR between 80 and 130 kDa. β-actin was probed as loading control.
(F). 32Dcl3 cells were transfected with siFbw7 and were either left unstimulated or stimulated with 100 ng/mL G-CSF for 2 (d2) and 3 days (d3) followed by WCEs preparation,
separation on SDS-PAGE and immunoblotted with anti-G-CSFR and anti-cdc4 antibodies to detect G-CSFR and Fbw7 respectively.
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is provided in Appendix A, Fig. S2.
Collectively, these results suggest that Fbw7 inhibits steady state
levels of G-CSFR by promoting its proteasomal degradation.
3.3. Fbw7α physically interacts with G-CSFR
Fbw7 is the substrate binding moiety of SCF ubiquitin ligase com-
plex and because G-CSFR is being targeted by Fbw7, we askedwhether Fbw7 physically associates with G-CSFR. To determine this,
we co-immunoprecipitated ectopically expressed G-CSFR from
WCEs of 293T transfected with G-CSFR and Fbw7α, Fbw7β or
Fbw7γ (Fig. 3A). We found that the three isoforms co-precipitated
with G-CSFR, verifying it to be a probable substrate of Fbw7. More-
over, to further identify the region of Fbw7 that interacts with
G-CSFR in vivo, we co-transfected G-CSFR with Fbw7α and its
deletion mutants Fbw7αΔF and dnFbw7αWD in 293T cells. We ob-
served that Fbw7α, Fbw7αΔF and dnFbw7αWD co-precipitated with
020
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Fig. 2. Fbw7 promotes G-CSFR degradation through ubiquitin–proteasome pathway. (A) 293T cells were co-transfected with 0.5 μg G-CSFR and either 1.0 μg (+) or 2.0 μg (++) of
Fbw7α. 48 h post transfection, MG132 (10 μM) and Baﬁlomycin A (300 nM) were added in indicated lanes for 6 h before harvesting cells. Expression of G-CSFR and Fbw7α was
assessed with anti-HA and anti-Flag-M2 antibodies respectively. β-actin was probed as loading control. (B) 293T cells were co-transfected with G-CSFR (1.0 μg) and His-Ubi either
alone or together with Fbw7 or its deletion mutants as indicated. After 48 h of transfection, MG132 (10 μM) was added in indicated condition 6 h before harvesting cells. Post 48 h,
cells were harvested, and G-CSFR was co-immunoprecipitated using anti-GFP antibody (G-CSFR is cloned in pMX-GFP vector). Co-precipitates were immunoblotted with anti-His
and anti-HA antibodies as indicated. (Ci) 293T cells were co-transfected with either 0.5 μg HA-G-CSFR or together with Fbw7α, or Fbw7αΔF or dnFbw7αWD. After 48 h, cells were
treated with 80 μg/mL of CHX andWCEs were prepared after 30, 60, 120 and 240 min and immunoblotted with anti-HA (Cii). The percentage of remaining G-CSFR calculated using
densitometry after various time points is graphically represented. Protein expression levels of Fbw7α, Fbw7αΔF or and dnFbw7αWD and their respective β-actin loading controls
are shown in Appendix A Fig. S2.
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in its WD domain. Our ﬁnding that Fbw7 interacts with G-CSFR
through its WD domain further approves the notion that G-CSFR
is a substrate of Fbw7. We observed an intensiﬁed interaction
between G-CSFR and Fbw7α in the presence of proteasome inhibi-
tors, MG132 and Lactacystin (Fig. 3C) which conﬁrms that Fbw7
binding with G-CSFR is prerequisite for ubiquitin mediated
proteasome degradation of G-CSFR. Furthermore, endogenous Fbw7
was also found to be interacting with exogenously expressed
G-CSFR (Appendix A, Fig. S3) that veriﬁed the direct interaction be-
tween the two. To further validate the in vivo interaction between
G-CSFR and Fbw7, we co-immunoprecipitated endogenous G-CSFR
from 32Dcl3 cells after G-CSF stimulation for 1 and 3 days and simulta-
neously from PBMCs treated with and without MG132 (to restore en-
dogenous G-CSFR). Fbw7 was detected when co-immunoprecipitates
were immunoblotted with Fbw7 antibody (Fig. 3D–E) which strongly
conﬁrms our ﬁnding that there is a physical interaction between
endogenous G-CSFR and Fbw7. Consistent with the physical inter-
action, endogenous G-CSFR and Fbw7 also co-localize together in
PBMCs (Fig. 3F) as well as in ectopically expressed 293T cells
(Fig. 3G). We observed that Fbw7α being localized in the nucleus and
nuclear periphery apparently co-localizes with G-CSFR at the nuclear
periphery.
Taken together, these data suggest that Fbw7 through its WD
domain physically associates and co-localizes with G-CSFR.3.4. Fbw7 interacts and degrades G-CSFR-T718 but at a quite slower rate
While there are several scattered CPDs in the G-CSFR protein se-
quence, many of them aremissing in G-CSFR-T718, reported in patients
with severe congenital neutropenia (SCN) transforming to AML [38].
This inspired us to investigate whether Fbw7 can also target this
truncated G-CSFR. To answer this, we co-transfected G-CSFR-T718
with Fbw7α, Fbw7β or Fbw7γ in 293T and found that Fbw7 also
downregulates G-CSFR-T718; however, G-CSFR-T718 downregulation
was quite slow compared to G-CSFR in the presence of Fbw7 isoforms
(Fig. 4A). We further assessed the down-modulation of G-CSFR-T718
with increasing amounts (0.5, 1.0 and 2.0 μg) of Fbw7α (Fig. 4B). We
found a slight decrease in G-CSFR-T718 with 2.0 μg of Fbw7α
suggesting Fbw7 indeed targets G-CSFR-T718 but not as efﬁciently as
the wild type G-CSFR. This is likely due to the absence of two fully con-
sensus putative CPDs from G-CSFR-T718. The above experiments when
performed in 32Dcl3 cells showed similar results; Fbw7 isoforms
downregulated G-CSFR-T718 however, at a slower rate as in Fig. 4C. In-
deed, CHX half-life determination of G-CSFR-T718 in the presence of
Fbw7α evidently conﬁrmed that Fbw7 degrades G-CSFR-T718 at a
slower rate compared to G-CSFR wild type (Fig. 4Di–ii). Clearly, these
ﬁndings indicate the importance of CPDs present in the carboxy-
terminal of G-CSFR after aa718. The reduced rate of degradation of
G-CSFR-T718 propelled us to examine if Fbw7 also interacts with
G-CSFR-T718. For this, we co-transfected 293T cells either with
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Fig. 3. Fbw7α physically interacts with G-CSFR. (A) Fbw7α, Fbw7β and Fbw7γ were co-transfected with G-CSFR. 48 h post transfection, whole cell extracts were prepared and
HA-G-CSFR was co-immunoprecipitated using anti-GFP antibody. Immunoblotting with anti-Flag-M2 antibody shows in vivo interaction between G-CSFR and all isoforms of
fbw7 (Fbw7α, Fbw7β and Fbw7γ). (B) 293T cells were co-transfected with 1.0 μg of G-CSFR and 1.0 μg of Fbw7α or its deletion mutants (Fbw7αΔF or dnFbw7αWD). 48 h after
transfection, MG132 (10 μM) was added in indicated lanes 6 h before WCEs were prepared. G-CSFR co-immunoprecipitation was performed with anti-GFP antibody followed by
immunoblotting of co-immunoprecipitates with anti-Flag-M and anti-HA antibodies. (C) 293T cells were co-transfected with 0.5 μg G-CSFR and 1.0 μg (+) of Fbw7α. 48 h post
transfection, MG132 (10 μM) and Lactacystin (10 μM) were added to 293T for 6 h before harvesting cells. WCEs were subjected to immunoprecipitation with anti-GFP antibody
and immunoprecipitates were probed ﬁrst with anti-Flag-M2 antibody followed by anti-HA antibody after stripping the same blot. In vivo interaction between G-CSFR and
Fbw7α is intensiﬁed in the presence of MG132 and Lactacystin (*unstripped Fbw7α below G-CSFR as the blot was ﬁrst immunoblotted with anti-Flag and then anti-HA; mild strip-
ping was performed to capture G-CSFR) (D) 32Dcl3 cells were stimulated with 100 ng/mL G-CSF for 2 (d2) and 3 days (d3). Endogenous G-CSFR was co-immunoprecipitated using
anti-G-CSFR antibody and co-immunoprecipitates were immunoblotted with anti-G-CSFR and anti-cdc4 antibodies respectively. (E) PBMCs isolated from volunteer's blood were
treated with 10 μM MG132 for 6 h. Endogenous G-CSFR was immunoprecipitated using anti-G-CSFR antibody and immunoprecipitates were immunoblotted with anti-cdc4 anti-
body. (F) PBMCs isolated from volunteer's blood were cytospun on slides. Immunoﬂuorescence (IFC) assay was performed as indicated in the Materials and methods using
anti-G-CSFR (rabbit) and anti-cdc4 (mouse) primary antibodies and anti-rabbit (Alexaﬂuor 488) and anti-mouse (Alexaﬂuor 594) secondary antibodies. Cells were air dried and
mounted to capture the images. (G) 293T cells were grown on coverslips and transfected with 0.5 μg G-CSFR and 0.5 μg Fbw7α. In order to avoid heavier degradation of
G-CSFR, IFC was performed after 24 h of transfection. Similar procedure as described in Fig. 3F was used.
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Fig. 4. Rate of degradation of mutant G-CSFR-T718 by Fbw7 is relatively slower than G-CSFR. (A) 293T cells were transiently co-transfected with 0.5 μg HA tagged G-CSFR-T718 and
indicated amounts of Fbws. After 48 h of transfection, WCEs were prepared, resolved on 8% SDS-PAGE and probed with anti-HA and anti-Flag antibodies to detect expression of
G-CSFR-T718 and Fbw7 isoforms (Fbw7α, Fbw7β and Fbw7γ). β-actin was probed as loading control. (B) 293T cells were co-transfected with 0.5 μg G-CSFR-T718 and increasing
amounts of Flag-Fbw7α (0.5, 1.0 and 2.0 μg). 48 h post transfection, lysates were prepared, resolved on SDS-PAGE and immunoblotted with anti-HA and anti-Flag-M2 antibodies. β
actin was probed as loading control. (C) 32Dcl3 cells were co-transfected with 0.5 μg HA tagged G-CSFR-T718 and indicated isoforms of Fbw7 (1.0 μg Fbw7α, Fbw7β and Fbw7γ)
separately. 48 h post transfection, WCEs were immunoblotted with anti-HA and anti-Flag-M2 (Di–ii) 293T cells were co-transfected with 0.5 μg HA-G-CSFR-T718 and Fbw7α. Post
48 h of transfection, cells were treated with 80 μg/mL of CHX and lysates were prepared after 30, 60, 120 and 240 min followed by immunoblotting with anti-HA antibody. The
percentage of remaining G-CSFR-T718 after various time points is depicted in the graph. Immunoblots for Fbw7α and β actin are shown in Appendix A Fig. S2. (E) 293T cells
were co-transfected with Fbw7 and either G-CSFR or G-CSFR-T718; 48 h post transfection, G-CSFR and G-CSFR-T718 were immunoprecipiated from lysates using anti-GFP antibody
and co-immunoprecipitates were probed with anti-HA and anti-Flag antibodies.
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cated prior to WCE preparation in order to stabilize G-CSFR in the
presence of Fbw7α. Anti-GFP antibody immunoprecipitated G-CSFR/
G-CSFR-T718 from WCEs and anti-Flag immunoblotting showed that
they still interactwith each other which probably is due to the presence
of the remaining CPDs in G-CSFR-T718 however, the observed slow
degradation of GSCFr-T718may be attributed to the absence of two po-
tential CPDs (Fig. 4E). To further corroborate our ﬁndings, we show that
endogenous Fbw7 interacts with ectopically expressed G-CSFR-T718
suggesting the direct in vivo interaction between the two (Fig. S3). In
fact, we also determined that besides Fbw7α, other two isoforms
Fbw7β and Fbw7γ also interact with G-CSFR-T718 (Fig. S3) which sug-
gests that region of G-CSFR required to interact with Fbw7 is also pres-
ent before aa718 in G-CSFR. Taken together, these data indicate that
Fbw7 also interacts with G-CSFR-T718 and targets it for degradation;however, its rate of degradation is relatively slower owing to the ab-
sence of some of CPD motifs which are otherwise present in wild type
G-CSFR.
3.5. Fbw7α mediated degradation of G-CSFR is GSK3β-dependent
Several groups have previously reported that substrates like c-jun,
c-myc, cyclin E and PGC-1α contain CPD motifs similar to the ones
present in G-CSFR and are phosphorylated by GSK3β within CPD
motifs prior to recognition and subsequent degradation by Fbw7
(Table 1). This inspired us to assess if GSK3β also instigates Fbw7α
mediated degradation of G-CSFR. To answer this, we transfected
293T cells with G-CSFR and Fbw7 and treated them with GSK3β in-
hibitor Lithium Chloride (LiCl) [39]. Immunoblotting with G-CSFR
showed that, like MG132, LiCl also restored G-CSFR expression in
2646 S. Lochab et al. / Biochimica et Biophysica Acta 1833 (2013) 2639–2652Fbw7α co-transfected condition (Fig. 5A), suggesting a probable role
of GSK3β in G-CSFR downregulation mediated through Fbw7. In line
with this, we examined G-CSFR half-life by inhibiting new protein
synthesis by CHX to determine the rate of degradation of G-CSFR
with Fbw7α in the presence of LiCl (Fig. 5B), we observed that as
expected, the rate of degradation of G-CSFR reduced in the presence
of LiCl. To substantiate further, we separately co-transfected G-CSFRA
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Fig. 5. G-CSFR degradation by Fbw7 isGSK3β-dependent. (A) 293T cellswere co-transfectedwith G-CSFR (0.5 μg) and Fbw7α (2.0 μg). 10 μMMG132was added for 6 h (36 h post trans-
fection) and 20 mM LiCl was added for 24 h (post 24 h transfection) in indicated lanes; thus after total of 48 h, lysates were prepared, resolved and immunoblotted with anti-HA and
anti-Flag-M2 antibodies. β-actin was probed as loading control. (B) 293T cells were transfected with 0.5 μg of each HA-G-CSFR and Fbw7α. 20 mM LiCl was added to transfected cells
in indicated lanes for 24 h. Cells were lysed 60 min after addition of CHX (80 μg/mL). G-CSFR and Fbw7 expression was compared to the conditions without CHX using anti-HA and
anti-Flag antibodies respectively; β-actin was probed as loading control. (C) 293T cells were co-transfected with 0.5 μg G-CSFR or G-CSFR-T718 together with increasing amounts of
GSK3β (0.5, 1.0 and 2.0 μg). 48 h post transfection, WCEs were prepared and subjected to immunoblotting with anti-HA and anti-GSK3β antibodies. Slow migrating band is V5 tagged
GSK3β while *marked faster migrating band is endogenous GSK3β. β-actin was used as loading control. (D). 293T cells were co-transfected with 0.5 μg of G-CSFR or G-CSFR-T718 and
0.5 μg of GSK3β S9A. 48 h post transfection, WCEs were subjected to immunoblotting with anti-HA and anti-GSK3β antibodies. (E) Increasing amounts of Fbw7 (0.5, 1.0 and 2.0 μg)
was transfected in 293T cells either alone or togetherwith siGSK3β (25 nM). 24 h post transfection, cellswere lysed, resolved on8%SDS-PAGE and immunoblottedwith anti-HA, anti-Flag
and anti-GSK3β antibodies. β-actin was immunoblotted as loading control. (F) 293T cells were co-transfected with G-CSFR and GSK3βwith/without Fbw7α, Fbw7αΔF or dnFbw7αWD.
WCEs prepared after 48 h of transfectionwere subjected to immunoblottingwith anti-HA and anti-Flag antibody. Inhibition of endogenous Fbw7with Fbw7αΔF or dnFbw7αWD inhibited
GSK3β instigated G-CSFR degradation; suggesting the inter dependence of both Fbw7 and GSK3β in degrading G-CSFR. (G) 293T cells were co-transfected with G-CSFR and increasing
amounts of either GSK3β alone (0.5, 1.0 and 2.0 μg) or together with siFbw7 (25 nM), lysates were prepared after 24 h of transfection and subjected to immunoblotting with anti-HA
and anti-Fbw7 antibodies; siFbw7 effectively knocked down endogenous Fbw7 as shown in Fig. S6. (H) 293T cells were transiently co-transfectedwith G-CSFR andG-CSFR-T718 together
with either GSK3β (H-i) or GSK3βS9A (H-ii) as indicated. 24 h post transfection, lysateswere prepared and G-CSFRwas co-immunoprecipitatedwith anti-G-CSFR antibody. Immunopre-
cipitates were subsequently probed with anti-GSK3β and anti-HA antibody. Endogenous GSK3β* and ectopically expressed V5-tagged GSK3β both co-precipitated with G-CSFR and
G-CSFR-T718 verifying an intense interaction between G-CSFR and GSK3β. GSK3βS9A has slightly higher molecular weight than endogenous GSK3β due to HA tagging. Therefore,
GSK3βS9A and endogenous GSK3β bands appear as doublet. (I) Endogenous GSK3β was immunoprecipitated using anti-GSK3β antibody from WCEs of 293 T cells transfected with
G-CSFR or G-CSFR-T718. Immunoblot with anti-HA shows in vivo interaction between ectopically expressed G-CSFR and/or G-CSFR-T718 with endogenous GSK3β.
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sion even in the absence of exogenous Fbw7. In fact G-CSFR completely
vanished with increasing doses of GSK3βS9A alone (Appendix A,
Fig. S4). We next asked whether Fbw7 driven degradation of G-CSFR
is GSK3β-dependent.We therefore, transfected 293T cells with increas-
ing amounts of Fbw7α (0.5, 1.0 and 2.0 μg) and silenced endogenous
GSK3β in 293T with siGSK3β. It showed that silencing of endogenous
GSK3β crippled Fbw7α driven degradation of G-CSFR (Fig. 5E);
suggesting GSK3β probably facilitates its kinase activity to G-CSFR forFbw7 mediated degradation. Because alleviated levels of GSK3β elimi-
nated G-CSFR and we hypothesized that GSK3 may phosphorylate
G-CSFR in its CPDs for its recognition by Fbw7, we therefore assessed
if GSK3β mediated downregulation of G-CSFR is dependent on Fbw7.
To answer this, we co-transfected G-CSFR or GSK3β either with Fbw7
or its deletion mutants (Fbw7αΔF and dnFbw7αWD) as indicated
in Fig. 5E. 24 h post transfection, WCEs were prepared, resolved on
10% SDS-PAGE and immunoblotted with the indicated antibodies.
We observed that GSK3β furthered degradation of G-CSFR when
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restored and stabilized when co-transfected with deletion mutants
even in the presence of exogenous GSK3β (Fig. 5F). Silencing endoge-
nous Fbw7 with siRNA also inhibited G-CSFR degradation even in
the presence of increasing doses of GSK3β (Fig. 5G) which further
conﬁrms the notion that Fbw7 and GSK3β are indispensible for
G-CSFR degradation.
To further substantiate the role of GSK3β in G-CSFR degradation
through Fbw7, we determined the in vivo interaction of GSK3β
with G-CSFR and G-CSFR-T718. For this, 293T cells were co-
transfected with G-CSFR or G-CSFR-T718 with GSK3β or GSK3βS9A.
Co-immunoprecipitation with G-CSFR antibody showed that en-
dogenous GSK3β also co-precipitated with ectopically expressed
GSK3β (V5-tagged-GSK3β migrates slowly compared to endogenous
GSK3β) and GSK3βS9A (band could be seen slightly above the en-
dogenous GSK3β due HA tagging) with G-CSFR and G-CSFR-T718.
The results showed that GSK3β efﬁciently interacts with both
G-CSFR and G-CSFR-T718 (Fig. 5Hi–ii). Further, we also performed co-
immunoprecipitation with endogenous GSK3β from 293T cells and
found that ectopically expressed G-CSFR and G-CSFR-T718 also co-
precipitated with endogenous GSK3β which again veriﬁes a direct in-
teraction between the two (Fig. 5I). To further provide substantial evi-
dence that GSK3β binds to G-CSFR and mediates its Fbw7 dependent
degradation, we show that all three proteins (GSK3β, G-CSFR/G-CSFR-
T718 and Fbw7) are present in the same complex by showing that
GSK3β co-precipitates with Fbw7 isoforms when G-CSFR and G-CSFR-
T718 were immunoprecipitated (Appendix A, Fig. S3).
Collectively, these results suggest that Fbw7 mediated degrada-
tion of G-CSFR and G-CSFR-T718 is GSK3β dependent.3.6. Fbw7 inhibits STAT3 activation while knockdown of Fbw7 or
ectopically expressed dnFbw7αWD enhances STAT3 activation
Previous studies have shown that STAT3 activation is required for
G-CSFR dependent normal proliferation and granulocytic differentia-
tion [24,40]. Therefore, we reasoned that degradation of G-CSFR by
Fbw7 also inhibits STAT3 activation and subsequent downstream
G-CSFR signaling. To address this, we ectopically over expressed
Fbw7α in murine myeloid cell line 32Dcl3 (a model system to study
neutrophil functions [41]) and post 24 h transfection, treated cells
with G-CSF for 10, 30 and 60 min respectively, As expected, STAT3
phosphorylation dramatically decreased upon Fbw7α over expres-
sion (Fig. 6A). Moreover, when 32Dcl3 cells were transfected with in-
creasing amounts of Fbw7α and induced with G-CSF for shorter
duration (10 min), G-CSF mediated STAT3 activation was again
inhibited suggesting Fbw7 mediated downregulation of G-CSFR in-
deed negatively inﬂuences its downstream signaling (Fig. 6B). To
consolidate these ﬁndings further, we assessed STAT3 phosphoryla-
tion by inhibiting endogenous Fbw7 either by knocking down Fbw7
through siFbw7 (Fig. 6D) or by over expressing dnFbw7αWD
(Fig. 6C) again in 32Dcl3 cells. Cells were induced with G-CSF for in-
dicated time points and lysates were immunoblotted with pSTAT3.
Massive phosphorylation of STAT3 in both conditions was observed
suggesting that inhibiting Fbw7 targeted degradation of G-CSFR
may restore G-CSFR signaling. To substantiate further, we performed
rescue experiment by expressing either DN-Fbw7 (dnFbw7αWD) or
knocking down Fbw7 by siFbw7 with simultaneous knock down of
G-CSFR by siG-CSFR and then assessed pSTAT3 expression. As
shown in the immunoblot in Fig. 6E and F; upon G-CSF treatment,
STAT3 phosphorylation (pSTAT3) are enhanced in both conditions
when dnFbw7αWD was expressed or Fbw7 was knocked down;
however this pSTAT3 substantially reduced when G-CSFR was also
knocked down simultaneously in the rescue experiment suggesting
STAT3 activation and subsequent enhanced granulocytic differentia-
tion are really because Fbw7 functions through G-CSFR.3.7. Knockdown of Fbw7 or ectopically expressed dnFbw7αWD triggers
differentiation in 32Dcl3 cells
The above assessment of the STAT3 activation/inhibition upon
Fbw7 knockdown or over expression in 32Dcl3 cells encouraged us
to verify the biological response of 32Dcl3 cells upon Fbw7 inhibition.
We therefore, examined the morphological changes in 32Dcl3 by
inhibiting endogenous Fbw7 expression/function with siFbw7 or
dnFbw7αWD over expression. Notably, IL-3 replacement with G-CSF
stimulates proliferation of these 32Dcl3 cells for 4–5 days followed
by growth arrest and apparent neutrophil like morphology by day
12. Moreover, G-CSF alone can drive 32Dcl3 cells to differentiation
[42,43]. We assessed if inhibition of Fbw7 triggers early and robust
differentiation in 32Dcl3 cells. For this, 32Dcl3 was either mock
transfected or transfected with siFbw7 and dnFbw7αWD separately;
grown in IL3 free medium containing G-CSF. Post 3, 9 and 15 days
of culture, Giemsa stained cells were assessed for their morphological
changes. Interestingly, on day 3 few granules like nuclear morphology
were observed in cells transfected with siFbw7 and dnFbw7αWD even
in the cells not treated with G-CSF (Fig. 7A). Moreover, by day 9 cells
attained myelocyte morphology with oval shaped nucleus with obvi-
ous differentiation like morphology even in G-CSF untreated mock
transfected cells in addition to siFbw7 and dnFbw7αWD transfected
cells (Fig. 7B). At day 15, cells appeared more like metamyelocytes
with nucleus being elongated, dense horseshoe or ring shaped and
few cells demonstrated polymorphonuclear neutrophil like morphol-
ogy with segmented nucleus (Fig. 7C) [34]. The fact that G-CSF stim-
ulation with siFbw7 or dnFbw7αWD transfection shows additive
effect andmore interestingly siFbw7 and dnFbw7αWD alone triggered
profound granulocytic differentiation in 32Dcl3 cells afﬁrms our ﬁnd-
ing that Fbw7 obstructs granulocytic differentiation apparently by
negatively regulating G-CSFR expression and functions.
3.8. siFbw7 or ectopically expressed dnFbw7αWD with simultaneous
knock down of G-CSFR by siG-CSFR is unable to induce granulocytic
differentiation
After validation of STAT activity by assessing pSTAT3 expression in
siFbw7 or ectopically expressed dnFbw7αWD with simultaneous
knock down of G-CSFR by siG-CSFR in Fig. 6E, F; we assessed granulo-
cyte differentiation like morphological changes in cells expressing
either dnFbw7αWD or siFbw7 alone or together with siG-CSFR in
32Dcl3 cells treated or untreated with G-CSF (Fig. 8). In line with re-
duced pSTAT3, almost no differentiation was seen even after 15 days
which further corroborates our claim that Fbw7 negatively regulates
G-CSFR expression and its downstream functions by targeting it for
degradation through the ubiquitin–proteasome pathway.
4. Discussion
In this study we have identiﬁed G-CSFR as a novel substrate of
Fbw7. Fbw7 has been shown to regulate the abundance of proteins
such as cyclin E, c-Myc, Notch, c-Jun, MCL-1, SREBP1, mTOR and
PGC-1α (Table 1). Our present study extends this list to G-CSFR
where we show that Fbw7 regulates G-CSFR expression. Previous
studies have demonstrated attenuation of G-CSFR signaling via
ubiquitin–proteasome pathway; however, the E3 ubiquitin ligases in-
volved have largely remained unexplored. The presence of several
putative CPD motifs in G-CSFR (Table 1) indicated that Fbw7 could
govern G-CSFR expression by targeting it for degradation. We found
that all the three isoforms of Fbw7 downregulated G-CSFR both in
non-myeloid (HEK293T) and myeloid cells (32Dcl3 and peripheral
blood mononuclear cells) (Fig. 1). Although, these isoforms are locat-
ed in different sub-cellular locations, they may still negatively
regulate G-CSFR by interacting with each other as reported in the
case of another substrate cyclin E1 [44]. Nonetheless, using the most
AB
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Fig. 6. siFbw7 or dnFbw7αWD transfection enhances STAT3 activation in 32Dcl3 cells. (A) 32Dcl3 cells were transfected with Fbw7α and 48 h post transfection, cells were stimu-
lated with 100 ng/mL G-CSF for 10, 30 and 60 min. WCEs were prepared and subjected to immunoblotting with anti-pSTAT3, anti-STAT3, anti-Flag and anti-β-actin antibodies.
(B) Increasing amounts of Fbw7α (0.5, 1.0 and 2.0 μg) were transfected in 32Dcl3, 24 h post transfection, cells were stimulated with 100 ng/mL G-CSF for 10 min followed by
WCE preparation. Lysates were resolved on 8% SDS-PAGE and probed with anti-pSTAT3 and anti-STAT3 antibody. (C) 2.0 μg dnFbw7αWD was transfected in 32Dcl23 and treated
with 100 ng/mL G-CSF for 10, 30 and 60 min followed by cell harvesting. Lysates were resolved on 8% SDS-PAGE and probed with pSTAT3 and STAT3 antibody (D) Endogenous
Fbw7 was silenced by transfecting siFbw7 (50 nM); post 24 h transfection, cells were stimulated with 100 ng/mL G-CSF followed by WCE preparation. WCEs were resolved on
8% SDS-PAGE and probed with anti-pSTAT3 and anti-STAT3 antibody. (E) Endogenous Fbw7 and G-CSFR were silenced by transfecting siFbw7 (50 nM) and siG-CSFR (50 nM) re-
spectively. Post 24 h transfection, cells were stimulated with 100 ng/mL G-CSF for 10 and 60 min followed by WCE preparation. WCEs were resolved on 8% SDS-PAGE and probed
with pSTAT3 and STAT3 antibody. (F) 2.0 μg dnFbw7αWD was co-transfected with 50 nM of siG-CSFR in 32Dcl23 and treated with 100 ng/mL G-CSF for 10 and 60 min followed by
cell harvesting. Lysates were resolved on 8% SDS-PAGE and probed with anti-pSTAT3 and anti-STAT3 antibody.
2649S. Lochab et al. / Biochimica et Biophysica Acta 1833 (2013) 2639–2652abundant and stable isoform Fbw7αwe further show that through its
WD domain, Fbw7 interacts with G-CSFR (Fig. 3) and targets it for
proteasome-dependent degradation (Fig. 2). Several independent
mutations in the gene encoding the G-CSFR have been reported in
myeloid diseases, including severe congenital neutropenia (SCN).
The most frequent mutations in SCN result in the introduction of
stop codons in the G-CSFR C-terminal region, the region implicated
in the induction of maturation and growth arrest [45]. The expression
of these truncated forms of G-CSFR in SCN patients are associated
with an increased risk of developing acute myeloid leukemia (AML)
due to hyperactivation of G-CSFR signaling [46]. C-terminal truncated
G-CSFR-T718 (deletion of c-terminal after aa 718) is one such mutant
that is frequently detected in SCN/AML patients. We observed that
Fbw7s like with G-CSFR, also interact with G-CSFR-T718 and target
it for degradation (Fig. 4 and Appendix A, Fig. S3); however, the
rate of G-CSFR-T718 degradation is far slower compared to G-CSFR.
Our ﬁnding may explain why cells expressing this truncated G-CSFRdo exhibit increased receptor expression at the membrane surface
but are unable to undergo granulocytic differentiation.
Literature search through known substrates of Fbw7 indicated
that prior phosphorylation of CPD motifs within substrates is a pre-
requisite for their recognition and subsequent degradation by Fbw7.
Previous studies have shown that GSK3β, a serine/threonine kinase
acts as an upstream modifying enzyme that phosphorylates the CPD
motifs present in some of the known Fbw7 substrates and triggers
their Fbw7 mediated degradation [47]. The presence of ﬁve such sim-
ilar motifs in G-CSFR encouraged us to hypothesize that GSK3βmight
also phosphorylate G-CSFR within putative CPD motifs for Fbw7 rec-
ognition and subsequent degradation. The fact that increasing doses
of GSK3β or GSK3S9A persistently inhibits the expression of both
G-CSFR and G-CSFR-T718 suggests that GSK3β may phosphorylate
G-CSFR probably in its CPDs marking it to be recognized by Fbw7
for efﬁcient degradation. Interestingly, even with GSK3β, the rate of
degradation of G-CSFR-T718 was again slower compared to G-CSFR.
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Fig. 7. Knockdown of Fbw7 or ectopically expressed dnFbw7αWD triggers differentiation in 32Dcl3 cells: 32Dcl3 cells in duplicates were either mock transfected or with siFbw7 or
dnFbw7αWD. One set was induced with 100 ng/mL of G-CSF while the other was left untreated. Cells were deprived of IL3. After 3, 9 and 15 days both G-CSF and untreated cells
were collected, cytospun and air dried. The next day cells were Giemsa stained and images were captured under microscope (Leica DMI6000B). (A) Day 3: few granules were ob-
served on G-CSF treated cells and cells transfected with siFbw7, dnFbw7αWD. (B) Day 9: G-CSF treated cells and siFbw7, dnFbw7αWD transfected cells attained myelocyte morphol-
ogy with oval shaped and elongated nucleus. (C) Day 15: differentiated cells show nucleus being elongated, dense with horseshoe or ring shaped. Few cells also demonstrated
polymorphonuclear neutrophil like morphology with segmented nucleus. Notably, as expected, cells treated with G-CSF showed neutrophil differentiation however surprisingly
G-CSF untreated cells transfected with siFbw7 and dnFbw7αWD alone also triggered massive neutrophil differentiation in 32Dcl3 cells. Arrows indicate differentiated cells.
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amino acid residues phosphorylated by GSK3β (creation of point
and deletion mutants is already underway; Appendix A, Fig. S5);nonetheless, restoration of G-CSFR expression in the presence of
LiCl or upon siRNA mediated knock down of either GSKβ or Fbw7
conﬁrms their indispensible interdependence for targeting G-CSFR
A
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Fig. 8. siFbw7 or ectopically expressed dnFbw7αWD with simultaneous knock down of G-CSFR by siG-CSFR is unable to induce granulocytic differentiation: 32Dcl3 cells were
co-transfected with siFbw7 or dnFbw7αWD together with siG-CSFR. 48 h post transfection, cells were stimulated with 100 ng/mL G-CSF. After 15 days, cells were cytospun, Giemsa
stained, air dried and photographed. Arrows indicate differentiated cells.
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ﬁrmed by the fact that these proteins G-CSFR, G-CSFR-T718, Fbw7s
and GSK3β are present in the same complex as demonstrated by
their in vivo interaction in co-immunoprecipitation study (Appendix A,
Fig. S3).
G-CSF mediates its biological effects by binding to its cognate re-
ceptor G-CSFR. Upon activation by G-CSF, G-CSFR is phosphorylated
at four conserved tyrosines that serve as docking sites for SH2
domain-containing signaling proteins such as signal transducer and
activator of transcription-3 (STAT3) and a variety of other down-
stream signaling proteins [48]. Activation of STAT3 is critical for nor-
mal G-CSF dependent proliferation and granulocytic differentiation of
myeloid progenitors [42]. Therefore, we asked if G-CSFR inhibition by
Fbw7 hampers its downstream signaling. To this end, over expressing
32Dcl3 cells with Fbw7α followed by treatment with G-CSF post 24 h
transfection showed regression of STAT3 phosphorylation suggesting
Fbw7 indeed hampers G-CSFR signaling. The negative effects of
Fbw7 on G-CSFR signaling were corroborated further by inhibiting
endogenous Fbw7 either with siFbw7 or dnFbw7αWD, which resulted
in enhanced STAT3 activation upon G-CSF stimulation in 32Dcl3 cells
(Fig. 6). Following Fbw7 mediated inhibition of G-CSFR downstream
signaling, we were now curious to know if targeting Fbw7 by
siFbw7 or dnFbw7αWD restores G-CSFR and its downstream signals
are transduced further in the form of granulocytic differentiation.
Therefore, we studied the morphology of 32Dcl3 cells transfected
with dnFbw7αWD or siFbw7 followed by treatment with G-CSF.
After 3, 9 and 15 days, Giemsa stained cells were analyzed for mor-
phological changes which showed enhanced granulocytic differentia-
tion. Cells appeared to be metamyelocytes with elongated nucleus,
horseshoe or ring shaped. In fact few cells possessed polymorphonu-
clear neutrophil like morphology with segmented nucleus. Although,
G-CSF is known to stimulate such morphological changes but surpris-
ingly siFbw7 and dnFbw7αWD alone also triggered dramatic differen-
tiation in 32Dcl3 even in the absence of G-CSF (Fig. 7). Additionally
when 32Dcl3 cells were supplemented with G-CSF along with
siFbw7 or dnFbw7αWD transfection, a rather additive differentiation
effect was seen. On the contrary, the fact that pSTAT3 and subsequent
granulocytic differentiation substantially mitigated when G-CSFR and
Fbw7 were simultaneously knocked down in a rescue experiment
further afﬁrms our ﬁnding that pSTAT3 activation and subsequentenhanced granulocytic differentiation is because Fbw7 functions
through G-CSFR to activate pSTAT3.
5. Conclusion
Our study demonstrates that Fbw7 in cooperation with GSK3β
negativelymodulates G-CSFR protein steady state levels by promoting
its degradation and thus regulates granulocytic differentiation. Like
other known substrates, through its WD domain Fbw7 physically in-
teracts with CPDmotifs of G-CSFR that are apparently phosphorylated
by GSK3β. Although detailed molecular study is underway to pull out
the exact CPD motifs and its GSK3β phosphomodiﬁed amino acids
among several CPDs present in G-CSFR. Nonetheless, siFbw7 and
dnFbw7αWD mediated inhibition of Fbw7 leading to activation of
STAT3 and subsequent induction of enhanced granulocytic differenti-
ation in 32Dcl3 even in the absence of G-CSF strongly vouches for our
ﬁnding that Fbw7 negatively regulates G-CSFR signaling. More impor-
tantly, our ﬁnding that Fbw7 andGSKβ induced degradation of G-CSFR
is faster than that of G-CSFR-T718 mutant lacking some of consensus
CPD motifs may be signiﬁcant for understanding pathophysiology of
SCN/AML patients and developing better therapeutics. Overall, these
ﬁndings suggest that Fbw7 with G-SK3β negatively regulates G-CSFR
signaling through ubiquitin–proteasome pathway.
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